These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 6815138)

  • 41. The effects of negative pions on spermatogonial survival in the mouse.
    Lambert BE; Phipps ML; Coggle JE; Davies RW; Peel DM
    Br J Radiol; 1982 Feb; 55(650):147-50. PubMed ID: 7055662
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preclinical evaluation of pions in vivo: experience at TRIUMF.
    Chaplin DJ; Douglas BG; Saito T; Skarsgard LD; Lam GK; Denekamp J
    Radiother Oncol; 1990 Jan; 17(1):7-15. PubMed ID: 2320741
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Trends in cancer therapy with new particle radiotherapy. Use of pi-mesons and heavy ion beam, with special reference to our own cases].
    Akanuma A
    Nihon Rinsho; 1980 Jun; 38(6):2501-15. PubMed ID: 6251296
    [No Abstract]   [Full Text] [Related]  

  • 44. Radiobiologic properties of pions and heavy ions. A comparison.
    Raju MR
    J Can Assoc Radiol; 1980 Mar; 31(1):26-9. PubMed ID: 7364843
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dose outside the treatment volume for irradiation with negative pions.
    Amols HI; Bradbury JN; Dicello JF; Helland JA; Kligerman MM; Lane TF; Paciotti MA; Roeder DL; Schillaci ME
    Phys Med Biol; 1978 May; 23(3):385-96. PubMed ID: 674356
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Radiobiology of pions at TRIUMF.
    Skarsgard LD; Palcic B; Douglas BG; Lam GK
    Int J Radiat Oncol Biol Phys; 1982 Dec; 8(12):2127-32. PubMed ID: 6761325
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Biomedical use and dosimetry of pions of the sin 590 MeV isochrone cyclotrone. VII. Radiation therapy using negative pions (author's transl)].
    Wideröe R
    Rofo; 1976 Feb; 124(2):182-5. PubMed ID: 131072
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New modalities in cancer treatment: heavy charged particles.
    Hall EJ
    Br J Radiol; 1981 Sep; 54(645):773-81. PubMed ID: 6271324
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tolerance of spinal cord, lung and rectum after fractionated pions and X-rays.
    van der Kogel AJ; Raju MR
    Strahlenther Onkol; 1989 Apr; 165(4):286-9. PubMed ID: 2711334
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of beam characteristics and detector size in negative-pion dose studies.
    Hamm RN; Wright HA; Turner JE
    Phys Med Biol; 1979 May; 24(3):613-20. PubMed ID: 461520
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radiobiological data for clinical dosimetry in pion tumour therapy.
    Heyder IR; Pohlit W
    Radiat Environ Biophys; 1979 Aug; 16(3):251-60. PubMed ID: 116310
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The three dose components of negative pion beam and their role in pion radiotherapy.
    Richman C; Rodriguez JF; Malcom JE; Stein ML
    Radiology; 1978 Sep; 128(3):757-66. PubMed ID: 97731
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Uniform depth dose distribution for biological irradiation using negative pions.
    Lam GK; Henkelman RM; Harrison RW; Skarsgard LD; Palcic B
    Phys Med Biol; 1979 Nov; 24(6):1243-9. PubMed ID: 119235
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of the therapy planning programs for the 60 beams SIN pion applicator.
    Pedroni E
    Radiat Environ Biophys; 1979 Aug; 16(3):211-7. PubMed ID: 116305
    [No Abstract]   [Full Text] [Related]  

  • 55. RBE and OER values of negative pion beams from growth inhibition of Vicia faba roots.
    Baarli J; Bianchi M; Hill CK; Sullivan AH; Tuyn JW
    Radiat Environ Biophys; 1979 Aug; 16(3):283-7. PubMed ID: 504559
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Integration of a real-time tumor monitoring system into gated proton spot-scanning beam therapy: an initial phantom study using patient tumor trajectory data.
    Matsuura T; Miyamoto N; Shimizu S; Fujii Y; Umezawa M; Takao S; Nihongi H; Toramatsu C; Sutherland K; Suzuki R; Ishikawa M; Kinoshita R; Maeda K; Umegaki K; Shirato H
    Med Phys; 2013 Jul; 40(7):071729. PubMed ID: 23822433
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biomedical program leading to therapeutic trials on pion radiation at Los Alamos.
    Kligerman MM; Knapp EA; Petersen DF
    Cancer; 1975 Nov; 36(5):1675-80. PubMed ID: 1192358
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pion treatment procedures and verification techniques.
    Zink SR; Bush SE; Gilman CJ; Hilko RH; Justice RK; Osborne EC; Smith AR; Berardo PA
    Int J Radiat Oncol Biol Phys; 1984 May; 10(5):723-35. PubMed ID: 6429096
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pions--the potential for therapeutic gain in locally advanced prostate cancer: dose escalation and toxicity studies.
    Pickles T; Bowen J; Dixon P; Gaffney C; Pomeroy M; Rheaume D; Vernimmen F; Goodman GB
    Int J Radiat Oncol Biol Phys; 1991 Sep; 21(4):1005-11. PubMed ID: 1917595
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preliminary results of a Phase I/II study with pi-meson (pion) treatment for bladder cancer.
    Studer UE; Von Essen CF; Enderli JB; Bodendörfer G; Zingg EJ
    Cancer; 1985 Oct; 56(8):1943-52. PubMed ID: 3928134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.